Bexorg, a biotech startup, is at the forefront of an innovative approach to studying neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Utilizing its BrainEx platform, the company connects donated human brains to a life-support system shortly after death, allowing them to remain viable for approximately 24 hours. This setup circulates oxygen and nutrients, enabling researchers to observe cellular and metabolic functions in real time. The brains are kept under anesthesia to suppress consciousness, addressing ethical concerns about awareness during experiments. Bexorg has analyzed over 700 brains, asserting that this method provides invaluable insights into the effects of genetics and environmental factors on neurodegenerative diseases. Pharmaceutical companies, including Biohaven, are already leveraging this technology to evaluate the efficacy of experimental drugs, demonstrating a significant shift in how neurodegenerative conditions may be studied and treated in the future. This groundbreaking research raises important ethical questions, particularly regarding the consciousness of the brains involved, which Bexorg claims is not present during the experiments.